| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angina Pectoris | 82 | 2019 | 109 | 7.710 |
Why?
|
| Vasodilator Agents | 20 | 2017 | 79 | 3.420 |
Why?
|
| Myocardial Infarction | 23 | 2018 | 342 | 3.360 |
Why?
|
| Heart Failure | 22 | 2021 | 232 | 3.190 |
Why?
|
| Myocardial Ischemia | 13 | 2019 | 73 | 2.260 |
Why?
|
| Nitrates | 14 | 2014 | 45 | 2.080 |
Why?
|
| Isosorbide Dinitrate | 23 | 2013 | 24 | 2.050 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2020 | 285 | 1.910 |
Why?
|
| Cardiovascular Agents | 4 | 2017 | 22 | 1.760 |
Why?
|
| Angina, Unstable | 5 | 2017 | 19 | 1.670 |
Why?
|
| Coronary Artery Disease | 6 | 2020 | 213 | 1.580 |
Why?
|
| Nitroglycerin | 22 | 2012 | 27 | 1.360 |
Why?
|
| Heart Rate | 32 | 2017 | 374 | 1.300 |
Why?
|
| Humans | 157 | 2021 | 26828 | 1.260 |
Why?
|
| Coronary Disease | 16 | 2009 | 118 | 1.220 |
Why?
|
| Angina, Stable | 3 | 2017 | 6 | 1.220 |
Why?
|
| Exercise Tolerance | 7 | 2020 | 82 | 1.180 |
Why?
|
| Calcium Channel Blockers | 16 | 2006 | 36 | 1.140 |
Why?
|
| Adrenergic beta-Antagonists | 21 | 2013 | 65 | 1.140 |
Why?
|
| Ventricular Function, Left | 6 | 2016 | 100 | 1.130 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 26 | 1.120 |
Why?
|
| Trimetazidine | 2 | 2019 | 2 | 0.920 |
Why?
|
| Drug Tolerance | 18 | 2014 | 37 | 0.900 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 66 | 0.890 |
Why?
|
| Cardiotonic Agents | 5 | 2016 | 25 | 0.890 |
Why?
|
| Treatment Outcome | 21 | 2021 | 2262 | 0.820 |
Why?
|
| Aspirin | 4 | 2017 | 119 | 0.810 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 346 | 0.810 |
Why?
|
| Piperazines | 4 | 2012 | 45 | 0.780 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2011 | 187 | 0.760 |
Why?
|
| Quality of Life | 4 | 2016 | 462 | 0.760 |
Why?
|
| Middle Aged | 83 | 2020 | 6813 | 0.760 |
Why?
|
| Male | 87 | 2021 | 12868 | 0.720 |
Why?
|
| Acute Coronary Syndrome | 2 | 2013 | 63 | 0.720 |
Why?
|
| Exercise Test | 31 | 2009 | 246 | 0.710 |
Why?
|
| Walk Test | 1 | 2020 | 20 | 0.690 |
Why?
|
| Aged | 54 | 2021 | 5159 | 0.670 |
Why?
|
| Hemodynamics | 24 | 2003 | 220 | 0.660 |
Why?
|
| Walking | 2 | 2020 | 130 | 0.640 |
Why?
|
| Trans Fatty Acids | 1 | 2018 | 1 | 0.640 |
Why?
|
| Benzazepines | 2 | 2017 | 12 | 0.630 |
Why?
|
| Shock, Cardiogenic | 2 | 2017 | 16 | 0.620 |
Why?
|
| Dietary Fats | 1 | 2018 | 55 | 0.620 |
Why?
|
| Double-Blind Method | 32 | 2021 | 399 | 0.600 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 233 | 0.600 |
Why?
|
| Female | 66 | 2021 | 14456 | 0.600 |
Why?
|
| Tachycardia, Sinus | 1 | 2017 | 8 | 0.590 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2013 | 63 | 0.590 |
Why?
|
| Blood Pressure | 33 | 2016 | 351 | 0.590 |
Why?
|
| Stroke | 2 | 2018 | 233 | 0.570 |
Why?
|
| Drug Therapy, Combination | 11 | 2016 | 203 | 0.550 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2006 | 12 | 0.550 |
Why?
|
| Hypertension | 11 | 2007 | 304 | 0.530 |
Why?
|
| Hospitalization | 3 | 2016 | 189 | 0.530 |
Why?
|
| Cardiac Catheterization | 6 | 2013 | 112 | 0.490 |
Why?
|
| Acetanilides | 3 | 2012 | 4 | 0.460 |
Why?
|
| Hemorrhage | 2 | 2013 | 259 | 0.460 |
Why?
|
| Stroke Volume | 9 | 2021 | 111 | 0.460 |
Why?
|
| Electrocardiography | 30 | 2009 | 391 | 0.460 |
Why?
|
| Nerve Growth Factors | 1 | 2013 | 24 | 0.450 |
Why?
|
| Time Factors | 21 | 2020 | 1563 | 0.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 58 | 0.450 |
Why?
|
| Physical Exertion | 20 | 1994 | 98 | 0.440 |
Why?
|
| Retroperitoneal Space | 1 | 2013 | 9 | 0.440 |
Why?
|
| Serpins | 1 | 2013 | 31 | 0.440 |
Why?
|
| Hydralazine | 2 | 2013 | 6 | 0.430 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 11 | 0.430 |
Why?
|
| Sodium Channel Blockers | 1 | 2012 | 11 | 0.420 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 3 | 0.420 |
Why?
|
| Obesity | 3 | 2021 | 650 | 0.410 |
Why?
|
| Veterans | 1 | 2013 | 66 | 0.400 |
Why?
|
| Diltiazem | 4 | 2002 | 5 | 0.390 |
Why?
|
| Eye Proteins | 1 | 2013 | 197 | 0.390 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2011 | 18 | 0.380 |
Why?
|
| Prospective Studies | 7 | 2021 | 1216 | 0.370 |
Why?
|
| Drug Administration Schedule | 13 | 2009 | 218 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 24 | 2011 | 586 | 0.360 |
Why?
|
| Primary Prevention | 1 | 2011 | 25 | 0.360 |
Why?
|
| Ticlopidine | 2 | 2009 | 34 | 0.360 |
Why?
|
| Diabetes Complications | 1 | 2011 | 66 | 0.360 |
Why?
|
| Delayed-Action Preparations | 14 | 2014 | 38 | 0.350 |
Why?
|
| Motor Activity | 1 | 2011 | 145 | 0.350 |
Why?
|
| Drug Interactions | 6 | 2014 | 77 | 0.340 |
Why?
|
| United States | 9 | 2021 | 2031 | 0.340 |
Why?
|
| Risk Factors | 9 | 2018 | 2006 | 0.330 |
Why?
|
| Amlodipine | 7 | 2007 | 8 | 0.330 |
Why?
|
| Nisoldipine | 3 | 2003 | 3 | 0.330 |
Why?
|
| Coronary Restenosis | 1 | 2009 | 20 | 0.320 |
Why?
|
| Postoperative Care | 1 | 2009 | 67 | 0.320 |
Why?
|
| Adult | 55 | 2016 | 7381 | 0.320 |
Why?
|
| Antihypertensive Agents | 4 | 2011 | 57 | 0.310 |
Why?
|
| Coronary Angiography | 10 | 2016 | 149 | 0.290 |
Why?
|
| Headache | 2 | 2006 | 30 | 0.280 |
Why?
|
| Hypolipidemic Agents | 4 | 2011 | 20 | 0.280 |
Why?
|
| Risk Assessment | 2 | 2020 | 586 | 0.280 |
Why?
|
| Erectile Dysfunction | 2 | 2003 | 13 | 0.270 |
Why?
|
| Clinical Trials as Topic | 15 | 2009 | 205 | 0.270 |
Why?
|
| Myocardial Revascularization | 2 | 2016 | 14 | 0.270 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2009 | 8 | 0.260 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 47 | 0.250 |
Why?
|
| Mibefradil | 2 | 2002 | 2 | 0.240 |
Why?
|
| Exercise | 5 | 2002 | 451 | 0.240 |
Why?
|
| Animals | 12 | 2018 | 9957 | 0.240 |
Why?
|
| Aged, 80 and over | 10 | 2016 | 1924 | 0.240 |
Why?
|
| Drug Therapy | 1 | 2004 | 15 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 356 | 0.230 |
Why?
|
| Propranolol | 11 | 1996 | 38 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 160 | 0.210 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2002 | 14 | 0.210 |
Why?
|
| Prognosis | 6 | 2021 | 759 | 0.210 |
Why?
|
| Myocardial Contraction | 5 | 1998 | 60 | 0.210 |
Why?
|
| Lisinopril | 3 | 2007 | 3 | 0.210 |
Why?
|
| Cardiovascular System | 1 | 2002 | 39 | 0.210 |
Why?
|
| Imidazoles | 1 | 2002 | 60 | 0.210 |
Why?
|
| Chronic Disease | 10 | 2009 | 263 | 0.200 |
Why?
|
| Stents | 2 | 2017 | 113 | 0.200 |
Why?
|
| Echocardiography | 6 | 2002 | 107 | 0.190 |
Why?
|
| Spironolactone | 1 | 2021 | 4 | 0.190 |
Why?
|
| Estradiol | 3 | 1998 | 174 | 0.180 |
Why?
|
| Systole | 3 | 2013 | 24 | 0.180 |
Why?
|
| Fibrinolytic Agents | 2 | 2016 | 67 | 0.170 |
Why?
|
| Aortic Rupture | 2 | 1991 | 8 | 0.170 |
Why?
|
| Prevalence | 3 | 2021 | 472 | 0.170 |
Why?
|
| Follow-Up Studies | 6 | 2013 | 980 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 472 | 0.170 |
Why?
|
| Recovery of Function | 1 | 2020 | 111 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2006 | 33 | 0.160 |
Why?
|
| Administration, Oral | 9 | 1997 | 166 | 0.160 |
Why?
|
| Nifedipine | 2 | 1989 | 12 | 0.160 |
Why?
|
| Nutritive Value | 1 | 2018 | 2 | 0.160 |
Why?
|
| Recommended Dietary Allowances | 1 | 2018 | 5 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1998 | 10 | 0.150 |
Why?
|
| Thrombolytic Therapy | 2 | 2016 | 36 | 0.150 |
Why?
|
| Incidence | 2 | 2018 | 545 | 0.150 |
Why?
|
| Mesalamine | 1 | 1998 | 5 | 0.150 |
Why?
|
| Nitrendipine | 1 | 1998 | 1 | 0.150 |
Why?
|
| Bradycardia | 1 | 1998 | 17 | 0.150 |
Why?
|
| Calcium Channels | 1 | 1998 | 32 | 0.150 |
Why?
|
| Liver Diseases | 1 | 1998 | 51 | 0.150 |
Why?
|
| Dobutamine | 1 | 1997 | 7 | 0.150 |
Why?
|
| Health Status | 1 | 2018 | 145 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 140 | 0.140 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1997 | 5 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 1997 | 29 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2002 | 36 | 0.140 |
Why?
|
| Pyrrolidines | 2 | 1988 | 11 | 0.140 |
Why?
|
| Cardiac Output | 10 | 1988 | 36 | 0.140 |
Why?
|
| Posture | 6 | 1979 | 39 | 0.140 |
Why?
|
| Atenolol | 3 | 1994 | 10 | 0.140 |
Why?
|
| Isradipine | 2 | 1994 | 2 | 0.140 |
Why?
|
| Chlorthalidone | 2 | 2007 | 2 | 0.140 |
Why?
|
| Plant Preparations | 1 | 2016 | 5 | 0.140 |
Why?
|
| Heart | 6 | 1996 | 219 | 0.140 |
Why?
|
| Ranolazine | 2 | 2012 | 2 | 0.140 |
Why?
|
| Registries | 2 | 2016 | 379 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2013 | 2429 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2012 | 12 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 78 | 0.130 |
Why?
|
| Digoxin | 1 | 2016 | 8 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 1997 | 270 | 0.130 |
Why?
|
| Peptides | 1 | 1998 | 280 | 0.130 |
Why?
|
| Femoral Artery | 2 | 2013 | 58 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2016 | 42 | 0.130 |
Why?
|
| Pyridines | 2 | 1990 | 99 | 0.130 |
Why?
|
| Oxprenolol | 8 | 1981 | 8 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2005 | 26 | 0.120 |
Why?
|
| Placebos | 9 | 1994 | 45 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 1994 | 100 | 0.110 |
Why?
|
| Anemia | 1 | 2013 | 41 | 0.110 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 1997 | 14 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2013 | 77 | 0.100 |
Why?
|
| Atrial Fibrillation | 2 | 2016 | 398 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 1994 | 216 | 0.100 |
Why?
|
| Sinus of Valsalva | 1 | 1991 | 12 | 0.100 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1991 | 15 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2005 | 322 | 0.100 |
Why?
|
| Random Allocation | 6 | 1988 | 148 | 0.100 |
Why?
|
| Single-Blind Method | 4 | 1995 | 43 | 0.100 |
Why?
|
| Aortic Valve Insufficiency | 4 | 1986 | 21 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 386 | 0.090 |
Why?
|
| African Americans | 1 | 2013 | 350 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2013 | 293 | 0.090 |
Why?
|
| Prazosin | 1 | 1990 | 3 | 0.090 |
Why?
|
| Chest Pain | 2 | 2005 | 25 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 298 | 0.090 |
Why?
|
| Intermittent Claudication | 1 | 1991 | 117 | 0.090 |
Why?
|
| Safety | 1 | 2009 | 32 | 0.080 |
Why?
|
| Potassium | 2 | 1980 | 41 | 0.080 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1979 | 146 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 23 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 64 | 0.080 |
Why?
|
| Heart Aneurysm | 3 | 1980 | 10 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 26 | 0.080 |
Why?
|
| Pregnancy | 2 | 2008 | 1130 | 0.080 |
Why?
|
| Aortic Valve Stenosis | 3 | 1988 | 84 | 0.080 |
Why?
|
| Ovariectomy | 2 | 1998 | 53 | 0.080 |
Why?
|
| Plethysmography, Impedance | 1 | 1988 | 17 | 0.080 |
Why?
|
| Cardiography, Impedance | 1 | 1988 | 7 | 0.080 |
Why?
|
| Syncope | 2 | 2006 | 10 | 0.080 |
Why?
|
| Cross-Over Studies | 4 | 2002 | 125 | 0.070 |
Why?
|
| Glucose | 2 | 1980 | 192 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 252 | 0.070 |
Why?
|
| Insulin | 2 | 1980 | 310 | 0.070 |
Why?
|
| Methods | 2 | 2004 | 27 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 1997 | 388 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 78 | 0.070 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1986 | 1 | 0.070 |
Why?
|
| Smoking Cessation | 2 | 2005 | 398 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 77 | 0.070 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1986 | 16 | 0.070 |
Why?
|
| Vasoconstriction | 2 | 1998 | 41 | 0.070 |
Why?
|
| Sulfones | 2 | 2003 | 7 | 0.070 |
Why?
|
| United States Food and Drug Administration | 2 | 1998 | 43 | 0.070 |
Why?
|
| Ricin | 2 | 1996 | 2 | 0.070 |
Why?
|
| Indoramin | 1 | 1986 | 1 | 0.070 |
Why?
|
| Recurrence | 3 | 2004 | 315 | 0.070 |
Why?
|
| Rest | 4 | 1981 | 93 | 0.070 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2005 | 4 | 0.070 |
Why?
|
| Ultrasonography | 1 | 1986 | 228 | 0.060 |
Why?
|
| Myocardium | 4 | 1997 | 171 | 0.060 |
Why?
|
| Vasodilation | 2 | 1997 | 114 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 2005 | 33 | 0.060 |
Why?
|
| Rabbits | 4 | 1998 | 272 | 0.060 |
Why?
|
| Indoles | 1 | 1986 | 98 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 3 | 1975 | 132 | 0.060 |
Why?
|
| Coronary Circulation | 3 | 1994 | 30 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 144 | 0.060 |
Why?
|
| Biological Availability | 3 | 1994 | 43 | 0.060 |
Why?
|
| Logistic Models | 3 | 2013 | 397 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2016 | 231 | 0.060 |
Why?
|
| Angioplasty, Balloon | 1 | 2004 | 21 | 0.060 |
Why?
|
| Drug Evaluation | 5 | 1987 | 11 | 0.060 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2003 | 3 | 0.060 |
Why?
|
| Life Style | 1 | 2004 | 83 | 0.060 |
Why?
|
| Practolol | 4 | 1980 | 5 | 0.060 |
Why?
|
| Propanolamines | 4 | 1980 | 16 | 0.060 |
Why?
|
| Vardenafil Dihydrochloride | 1 | 2002 | 1 | 0.050 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Indomethacin | 1 | 1983 | 15 | 0.050 |
Why?
|
| Triazines | 1 | 2002 | 11 | 0.050 |
Why?
|
| Diastole | 1 | 2002 | 22 | 0.050 |
Why?
|
| Calcium Channels, T-Type | 1 | 2002 | 2 | 0.050 |
Why?
|
| Lactates | 2 | 1979 | 18 | 0.050 |
Why?
|
| Calcium Channels, L-Type | 1 | 2002 | 7 | 0.050 |
Why?
|
| Injections, Intravenous | 4 | 2002 | 65 | 0.050 |
Why?
|
| Contraindications | 2 | 2012 | 13 | 0.050 |
Why?
|
| Isoproterenol | 3 | 1998 | 23 | 0.050 |
Why?
|
| Adolescent | 5 | 2016 | 2955 | 0.050 |
Why?
|
| Epinephrine | 3 | 1998 | 36 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1998 | 42 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2016 | 45 | 0.050 |
Why?
|
| Ointments | 2 | 1994 | 6 | 0.050 |
Why?
|
| Administration, Topical | 2 | 1994 | 28 | 0.050 |
Why?
|
| Administration, Cutaneous | 2 | 1994 | 18 | 0.050 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 2 | 1998 | 7 | 0.050 |
Why?
|
| Calcium Channel Agonists | 2 | 1998 | 7 | 0.050 |
Why?
|
| Diuretics | 1 | 2021 | 12 | 0.050 |
Why?
|
| Disopyramide | 1 | 1981 | 10 | 0.050 |
Why?
|
| Muscle Contraction | 2 | 1998 | 161 | 0.040 |
Why?
|
| Coronary Vessels | 3 | 1998 | 151 | 0.040 |
Why?
|
| Circadian Rhythm | 3 | 1997 | 75 | 0.040 |
Why?
|
| Histamine | 1 | 1998 | 9 | 0.040 |
Why?
|
| Serotonin | 1 | 1998 | 16 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1998 | 2 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 1998 | 11 | 0.040 |
Why?
|
| Diethylstilbestrol | 1 | 1998 | 2 | 0.040 |
Why?
|
| Radionuclide Imaging | 3 | 1986 | 56 | 0.040 |
Why?
|
| Blood Glucose | 3 | 2006 | 300 | 0.040 |
Why?
|
| Papillary Muscles | 1 | 1998 | 14 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2013 | 50 | 0.040 |
Why?
|
| Oxygen Consumption | 3 | 1996 | 173 | 0.040 |
Why?
|
| Hospital Mortality | 2 | 2016 | 146 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 28 | 0.040 |
Why?
|
| Atropine | 1 | 1997 | 47 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 2580 | 0.040 |
Why?
|
| Bepridil | 2 | 1988 | 2 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1997 | 100 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 2 | 1975 | 15 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1997 | 117 | 0.030 |
Why?
|
| Pericarditis, Constrictive | 2 | 1975 | 3 | 0.030 |
Why?
|
| American Heart Association | 1 | 2016 | 21 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 20 | 0.030 |
Why?
|
| Drug Costs | 1 | 2016 | 17 | 0.030 |
Why?
|
| Heart Ventricles | 5 | 1979 | 127 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2016 | 29 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2016 | 30 | 0.030 |
Why?
|
| Heart Arrest | 1 | 2016 | 26 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2016 | 45 | 0.030 |
Why?
|
| Survival Rate | 1 | 1996 | 406 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 26 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 108 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 1975 | 8 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2016 | 73 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 65 | 0.030 |
Why?
|
| Anemia, Aplastic | 1 | 1975 | 3 | 0.030 |
Why?
|
| Splenomegaly | 1 | 1975 | 10 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1975 | 50 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 1975 | 22 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 215 | 0.030 |
Why?
|
| Calcium | 1 | 1995 | 231 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 250 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 1975 | 38 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 1994 | 44 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1997 | 305 | 0.030 |
Why?
|
| Dosage Forms | 1 | 1994 | 5 | 0.030 |
Why?
|
| Pulmonary Veins | 1 | 1975 | 107 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pentaerythritol Tetranitrate | 1 | 1993 | 1 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 716 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 207 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1973 | 14 | 0.030 |
Why?
|
| Amino Alcohols | 1 | 1973 | 3 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 3 | 1987 | 163 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1993 | 44 | 0.030 |
Why?
|
| In Vitro Techniques | 3 | 1998 | 239 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 213 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 189 | 0.030 |
Why?
|
| Regional Blood Flow | 2 | 1991 | 159 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 201 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2013 | 91 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 116 | 0.030 |
Why?
|
| Lung Diseases | 1 | 1973 | 41 | 0.030 |
Why?
|
| Heart Murmurs | 1 | 1991 | 2 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1991 | 18 | 0.020 |
Why?
|
| Dyspnea | 1 | 1991 | 25 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1994 | 747 | 0.020 |
Why?
|
| Femoral Vein | 1 | 1971 | 13 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 450 | 0.020 |
Why?
|
| Arteriovenous Fistula | 1 | 1971 | 16 | 0.020 |
Why?
|
| Catheterization | 1 | 1971 | 50 | 0.020 |
Why?
|
| Acute Disease | 3 | 1986 | 153 | 0.020 |
Why?
|
| Pericarditis | 1 | 1971 | 14 | 0.020 |
Why?
|
| Infusions, Intravenous | 3 | 2002 | 99 | 0.020 |
Why?
|
| Half-Life | 2 | 2002 | 32 | 0.020 |
Why?
|
| Infusions, Parenteral | 2 | 1982 | 34 | 0.020 |
Why?
|
| Vascular Resistance | 2 | 1997 | 50 | 0.020 |
Why?
|
| Leg | 1 | 1991 | 131 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 733 | 0.020 |
Why?
|
| Metoprolol | 2 | 1980 | 2 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 1998 | 408 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 508 | 0.020 |
Why?
|
| Radiography | 3 | 1992 | 200 | 0.020 |
Why?
|
| Lung | 3 | 1978 | 349 | 0.020 |
Why?
|
| Arousal | 1 | 1988 | 38 | 0.020 |
Why?
|
| Respiration | 2 | 1986 | 45 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1988 | 39 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 446 | 0.020 |
Why?
|
| Aorta, Thoracic | 2 | 1998 | 49 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1998 | 77 | 0.020 |
Why?
|
| Pressure | 2 | 1998 | 88 | 0.020 |
Why?
|
| Myxoma | 1 | 1987 | 6 | 0.020 |
Why?
|
| Isosorbide | 1 | 1987 | 1 | 0.020 |
Why?
|
| Heart Neoplasms | 1 | 1987 | 16 | 0.020 |
Why?
|
| Nitric Oxide | 2 | 1998 | 151 | 0.020 |
Why?
|
| Pulmonary Artery | 2 | 1979 | 68 | 0.020 |
Why?
|
| Mouth Floor | 1 | 1986 | 2 | 0.020 |
Why?
|
| Valsalva Maneuver | 1 | 1986 | 8 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2007 | 91 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1986 | 15 | 0.020 |
Why?
|
| Angioedema | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 3 | 0.020 |
Why?
|
| Angiography | 1 | 1986 | 35 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2006 | 37 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2006 | 76 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2006 | 48 | 0.020 |
Why?
|
| Risk | 1 | 2006 | 133 | 0.020 |
Why?
|
| Kinetics | 2 | 1983 | 538 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2007 | 859 | 0.020 |
Why?
|
| Pericardium | 2 | 1975 | 47 | 0.020 |
Why?
|
| Long-Term Care | 1 | 1984 | 30 | 0.010 |
Why?
|
| Sildenafil Citrate | 1 | 2003 | 4 | 0.010 |
Why?
|
| Purines | 1 | 2003 | 14 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1983 | 36 | 0.010 |
Why?
|
| Pulmonary Edema | 2 | 1975 | 9 | 0.010 |
Why?
|
| Thermodilution | 1 | 1982 | 2 | 0.010 |
Why?
|
| Radionuclide Angiography | 1 | 2002 | 2 | 0.010 |
Why?
|
| Physical Endurance | 1 | 1983 | 86 | 0.010 |
Why?
|
| Technetium | 1 | 1982 | 43 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1982 | 83 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 18 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 93 | 0.010 |
Why?
|
| Heart Atria | 2 | 1987 | 171 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1980 | 5 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1980 | 65 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1979 | 22 | 0.010 |
Why?
|
| Arteries | 1 | 1979 | 64 | 0.010 |
Why?
|
| Pinacidil | 1 | 1998 | 1 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1998 | 10 | 0.010 |
Why?
|
| Perfusion | 1 | 1998 | 43 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1998 | 34 | 0.010 |
Why?
|
| Rheumatoid Factor | 2 | 1975 | 28 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1998 | 73 | 0.010 |
Why?
|
| Adenosine | 1 | 1998 | 33 | 0.010 |
Why?
|
| Ventricular Function | 1 | 1978 | 25 | 0.010 |
Why?
|
| Nigeria | 1 | 1978 | 17 | 0.010 |
Why?
|
| Capillaries | 1 | 1978 | 32 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 1997 | 3 | 0.010 |
Why?
|
| Ventricular Fibrillation | 3 | 1972 | 40 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1997 | 73 | 0.010 |
Why?
|
| Dihydroalprenolol | 1 | 1996 | 1 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 19 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1996 | 19 | 0.010 |
Why?
|
| Mitochondria, Heart | 1 | 1995 | 23 | 0.010 |
Why?
|
| Pericardial Effusion | 1 | 1975 | 12 | 0.010 |
Why?
|
| Angiocardiography | 1 | 1975 | 7 | 0.010 |
Why?
|
| Autopsy | 1 | 1975 | 24 | 0.010 |
Why?
|
| Hydroxybutyrate Dehydrogenase | 2 | 1972 | 2 | 0.010 |
Why?
|
| Organ Size | 1 | 1975 | 83 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 1974 | 7 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 2 | 1972 | 20 | 0.010 |
Why?
|
| Splenectomy | 1 | 1975 | 43 | 0.010 |
Why?
|
| Thromboembolism | 1 | 1975 | 57 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 1975 | 30 | 0.010 |
Why?
|
| Spleen | 1 | 1975 | 109 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1975 | 367 | 0.010 |
Why?
|
| Propylamines | 1 | 1973 | 3 | 0.010 |
Why?
|
| Thrombosis | 1 | 1975 | 147 | 0.010 |
Why?
|
| Epithelium | 1 | 1973 | 39 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 970 | 0.010 |
Why?
|
| Vanilmandelic Acid | 1 | 1972 | 1 | 0.010 |
Why?
|
| 17-Hydroxycorticosteroids | 1 | 1972 | 1 | 0.010 |
Why?
|
| Necrosis | 1 | 1973 | 81 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1973 | 74 | 0.010 |
Why?
|
| Mitral Valve | 2 | 1987 | 58 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1972 | 88 | 0.010 |
Why?
|
| Liver | 1 | 1975 | 415 | 0.010 |
Why?
|
| Lidocaine | 1 | 1971 | 27 | 0.010 |
Why?
|
| Tachycardia | 2 | 1987 | 72 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1971 | 54 | 0.010 |
Why?
|
| Inflammation | 1 | 1973 | 601 | 0.000 |
Why?
|
| Catecholamines | 1 | 1988 | 18 | 0.000 |
Why?
|
| Aortic Valve | 2 | 1980 | 90 | 0.000 |
Why?
|
| Heart Valve Prosthesis | 2 | 1980 | 60 | 0.000 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1987 | 15 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1987 | 63 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1987 | 58 | 0.000 |
Why?
|
| Drug Stability | 1 | 1981 | 23 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1981 | 64 | 0.000 |
Why?
|
| Heart Function Tests | 1 | 1980 | 10 | 0.000 |
Why?
|
| Cardiomegaly | 1 | 1980 | 18 | 0.000 |
Why?
|
| Protein Binding | 1 | 1981 | 631 | 0.000 |
Why?
|
| Rheumatoid Nodule | 1 | 1975 | 1 | 0.000 |
Why?
|
| Phenyl Ethers | 1 | 1975 | 3 | 0.000 |
Why?
|
| Granuloma | 1 | 1975 | 17 | 0.000 |
Why?
|
| Eye Diseases | 1 | 1975 | 31 | 0.000 |
Why?
|
| Cineangiography | 1 | 1974 | 8 | 0.000 |
Why?
|
| Motion Pictures | 1 | 1974 | 3 | 0.000 |
Why?
|
| Diet, Reducing | 1 | 1974 | 10 | 0.000 |
Why?
|
| Body Weight | 1 | 1974 | 246 | 0.000 |
Why?
|
| Adrenal Glands | 1 | 1972 | 21 | 0.000 |
Why?
|
| Pain | 1 | 1974 | 252 | 0.000 |
Why?
|
| Blood Gas Analysis | 1 | 1971 | 9 | 0.000 |
Why?
|